ANDA 77082, held by Teva Pharmaceuticals. Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 77082 (Paroxetine Hydrochloride), held by Teva Pharmaceuticals, was first approved by FDA on Jun 29, 2007, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2007 | Original application | Approved | None posted |
| Paroxetine HydrochlorideEQ 10MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 20MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 30MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Paroxetine HydrochlorideEQ 40MG BASE · tablet;oral | Paroxetine Hydrochloride | Discontinued |
| Jun 3, 2008 | Supplement 1Labeling | Approved | None posted |
| Jun 29, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters